Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
ID: 355759Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355759

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-023.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at supporting exploratory research into the role of RNA modifications in brain aging and Alzheimer's disease (AD) and related dementias. This R21 grant seeks innovative proposals that investigate novel mechanisms of RNA modifications and their implications for the progression of AD and related dementias, with a focus on identifying RNA modification sites, exploring epitranscriptomic changes, and characterizing RNA modifying proteins. The total funding available is $1.4 million for up to five awards, with a maximum budget of $275,000 per project over two years. Interested applicants must submit their proposals by November 1, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-023-Full-Announcement.html
    RFA-AG-25-023.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD." This R21 grant aims to support exploratory research into the role of RNA modifications in brain aging and Alzheimer's disease (AD) and related dementias. The program seeks innovative proposals to investigate novel RNA modification mechanisms and their implications for AD/ADRD progression. Key research areas include identifying RNA modification sites linked to dementia, exploring epitranscriptomic changes, and characterizing RNA modifying proteins. Eligible applicants include higher education institutions, nonprofits, and government agencies. The funding amount available is $1.4 million for up to five awards, with a maximum budget of $275,000 over two years. Applications must adhere to strict submission guidelines and key dates, including a submission deadline of November 2, 2024. All research aims to foster precision medicine approaches for AD/ADRD by unveiling the complexities of RNA modifications and their functional impacts, ultimately aiding in disease prediction and therapeutic strategies.
    Similar Opportunities
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)," aimed at fostering innovative research methodologies to study brain activity and structural changes over extended periods. This initiative encourages multidisciplinary collaborations to develop novel approaches or adapt existing techniques for measuring brain function across diverse age groups and clinical populations, with a focus on longitudinal data collection at multiple time points. The funding, capped at $275,000 over a two-year period, is intended for high-risk, high-reward exploratory research that enhances understanding of brain development and aging, with applications due by May 16, 2024, and subsequent deadlines. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-161.html.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 Clinical Trial Not Allowed grant, aimed at advancing research into the cellular and molecular biology of complex brain disorders. This funding opportunity encourages innovative research focused on high-confidence risk factors associated with conditions such as schizophrenia, major depression, and anxiety, emphasizing hypothesis-generating studies rather than disorder modeling. The grant supports projects with budgets up to $275,000 over a two-year period, with applications due starting January 16, 2025, and a closing date of September 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html.
    Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)" aimed at exploring the manipulation of neural coordination to enhance cognitive, affective, or social processing. This grant encourages innovative research projects that investigate how specific alterations in neural activity patterns can impact cognitive functions and address molecular abnormalities related to neuropsychiatric disorders. With a budget cap of $275,000 over two years, eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments. Proposals must adhere to strict application guidelines and demonstrate potential real-world impacts on cognitive health, with applications due by January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-176.html.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.